Although these characteristics make XTS a promising therapeutic alternative, its development stage inherently has limitations: (1) Human pharmacokinetic data remain limited compared to clinically validated drugs; (2) The optimal dose to balance IL-23 inhibition with organ protection requires further validation; (3) For patients with concomitant autoimmune diseases, the long-term immunomodulatory effects require more comprehensive toxicological assessment. The gene discussed is IL23A; the disease is autoimmune disease.